Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Dronabinol on Blood Pressure Control
NCT07231965Phase 3
Key facts
- Status
- Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- Mayo Clinic
- Modality
- Small Molecules
- Drugs
- dronabinol
01
Overview
Phase 3, randomised trial comparing Dronabinol Group with Placebo Group (2 arms). Primary endpoints: Blood Pressure at 30 days and Heart Rate at 30 days. Planned start Oct 2026; status: not yet recruiting.
02
Design
2 arms- Study design
- Randomized
Dronabinol Group
Patients taking Dronabinol first and Placebo second
Placebo Group
Patients taking Placebo first and Dronabinol second
03
Who it enrols
Healthy occasional cannabis users aged 21-40 with BMI <= 35, without psychiatric disorders, hypotension, seizures, or history of substance abuse.
04
Endpoints
Primary
Blood Pressure
Heart Rate
Secondary
Baroreflex Sensitivity
Sympathetic control
Flow Mediated Dilation
Aortic Wave Reflection
Beyond the preview
Go deeper on NCT07231965.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231965.